Abstracts

**NEURO-ONCOLOGY** • NOVEMBER 2010

**ONGOING CLINICAL TRIALS**

**OT-01. IS SURGERY AT PROGRESSION A PROGNOSTIC MAKER FOR IMPROVE-MONTH PROGRESSION-FREE SURVIVAL OR OVERALL SURVIVAL FOR PATIENTS WITH RECURRENT GLOBLASTOMA?**

J. L. Clarke1, Michele M. Emms2, Kathleen R. Lamborn1, and Michael D. Prados1, 1UCSF; 2Quintiles

Historically, the North American Brain Tumor Consortium (NABTC) has used 6-month progression-free survival (PFS6) as the primary endpoint in Phase II clinical trials for recurrent glioma. Measurable disease has not been required and patients with recent surgeries have been eligible. In some trials, a subset of patients has received the trial agent before surgery to allow for the assessment of tumor uptake and biologic activity. With increased interest in targeted therapies, trials are now being designed to include only surgical candidates. When surgery is part of the trial, time-to-event is measured from the first post-surgery treatment. We compared PFS6 and overall survival (OS) for patients with glioblastoma (GBM) who underwent surgery at the time of progression to results for those who did not undergo surgery to evaluate the impact of surgical inter-vention on outcomes. All trials had similar entry criteria. Two data sets were analyzed. The first trial included 424 patients enrolled prior to 2003, of whom 65 had surgery (excluding biopsies) on study or within 30 days prior to registration. Analysis was stratified based on whether temozolomide was part of the protocol treatment regimen. No statistically significant difference in PFS6 or OS was found ($P > 0.4$ for both analyses). These analyses were repeated for 246 patients on seven recent trials: 68 who had surgery while on the clinical trial, 35 who had surgery for disease progression but not as part of the trial, and 143 who did not have surgery at the time of progression. PFS6 was 6%, 9%, and 6% for the 3 groups, respectively, with no difference in OS ($P > 0.5$ for both analyses). Conclusion: Results from two separate data sets indicate that PFS6 and OS results for patients having surgery at the time of disease progression are similar to the results for those who do not have surgery, allowing data from both types of patients to be combined in assessing the benefits of new treatments. Presented on behalf of the NABTC investigators.

**OT-02. PHASE I STUDY OF VORINOSTAT COMBINED WITH ISOTRETINOIN AND CARBOPLATIN IN ADULTS WITH RECURRENT MALIGNANT GLIOMAS**

Vmaya K. Puduvalli1, Marta Penas-Prado2, Mark R. Gilbert1, Morris D. Groves1, Kenneth R. Hess3, Victor A. Levin3, John de Groot3, Howard Colman3, Charles A. Conrad3, Monica E. Loghin3, Kathy Hunter3, and W K. Yung3; 1The University of Texas MD Anderson Cancer Center; 2Hospital Universitario de Canarias, Santa Cruz de Tenerife; 3Howard University Hospital, Washington DC

BACKGROUND: Epigenetic processes, such as DNA methylation and histone acetylation, constitute novel therapeutic targets against glioblastoma (GBM). Vorinostat, a histone deacetylase inhibitor (HDACi), has shown pre-clinical activity in adults with recurrent GBM. Preclinical studies have also demonstrated that vorinostat can overcome resistance to agents currently under investigation for recurrent GBM, such as isotretinoin and carboplatin. We hypothesized that vorinostat could overcome isotretinoin-resistance and synergize with carboplatin to target gliomas. We report the results of the Phase I study of combinations of these agents preceding an adaptive randomized 3-arm Phase II study due to open shortly. METHODS: Adults with recurrent malignant glioma, KPS ≥ 60, normal organ function, and no prior exposure to vorinostat/other HDAC inhibitors or carboplatin were enrolled into one of three arms. Arm 1: Vorinostat + Isotretinoin, Arm 2: Carboplatin + Isotretinoin, or Arm 3: Vorinostat + Isotretinoin + Carboplatin. Dose escalation was by a 3+3 design that defined the maximum tolerated dose (MTD) as the lowest dose that caused dose-limiting toxicity (DLT) in <2/6 patients. RESULTS: Toxicities among the 27 evaluable patients enrolled to date include (Arm 1) neutropenia, thrombocytopenia, pulmonary embolism, elevated AST (DLT), and hypertyrosicideremia (DLT); (Arm 2)–neutropenia, thrombocytopenia (DLT), and hypertyrosicideremia; (Arm 3) thrombocytopenia (DLT) and hypokalemia (DLT). The MTD has been identified in Arm 1 (vorinostat, 400 mg/d on days 1–7 and 15–21; isotretinoin, 100 mg/m2/d x 21 d) and Arm 2 (carbo-platin, AUC 6; isotretinoin, 100 mg/m2/d x 21 d); Arm 3 has undergone dose escalation to level 2 (vorinostat, 300 mg/day on days 1–7 and 15–21; isotretinoin, 100 mg/m2/d x 21 d; carboplatin, AUC 6) and has accrued 2 patients. The best response has been stable disease in 12 patients; 4 patients achieved 6-month progression-free survival (PFS). CONCLUSIONS: The combinations of vorinostat, isotretinoin, and carboplatin were well tolerated; the MTD has been established for Arms 1 and 2 and is expected to be determined shortly in Arm 3. Preliminary evidence of activity has been seen in these heavily pretreated patients, and the multi-center adaptive randomized Phase II study will open for accrual shortly.

**OT-03. PHASE I DOSE ESCALATION TRIAL OF VANDETANIB WITH FRACTIONATED RADIOSURGERY IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS**

Changhu Chen, Denise Damek, Arthur Liu, Laurie E. Gaspar, Allen Waziri, Kevin Lillehei, and Brian Kavanagh; University of Colorado School of Medicine

PURPOSE: To determine the maximum tolerated dose (MTD) of vandetanib with SRS in recurrent malignant gliomas. PATIENTS & METHODS: Patients with recurrent malignant glioma and T1-enhancing recurrent tumor of ≤ 6 cm were eligible. Vandetanib was administered 7 days prior to SRS and continued until dose-limiting toxicity (DLT) or disease progression. The vandetanib doses for Cohorts 1, 2, and 3 were 100 mg, 200 mg, and 300 mg, respectively. The study drug was given orally once a day. A total SRS dose of 36 Gy was delivered over 3 consecutive days. A standard 3+3 design was used. The MTD was defined as the dose of vandetanib at which less than 33% of patients developed DLTs, defined by the CTCAE version 3.0 as any grade 3 or higher nonhematologic toxicity or grade 4 or higher hemato-colon toxicity. RESULTS: Three patients got enrolled into one of three arms. Ten patients were treated on the protocol, and 9 patients had follow-up data. Characteristics of the 10 treated patients were: 7 men, 3 women; median age, 40 years (range, 22–72); 7 patients had glioblastoma (GBM), 3 had anaplastic astrocytoma (AA); median prior radiotherapy (RT) dose, 60 Gy (range, 59.4–70); median interval since prior RT, 14.5 months (range, 7–123). Median time on vandetanib was 3 months (range, 1–11) and all patients received SRS per protocol. The median follow-up time from SRS was 4 months (range, 1–10 months). Three of 6 patients were censored at a grade 3 DLT of pulmonary embolism and hemorhax. The trial was stopped when two of the four patients enrolled to the second cohort developed DLTs. CONCLUSION: Vandetanib MTD is 100 mg daily. This dose was well tolerated with 36 Gy SRS in recurrent malignant gliomas.

**OT-04. HEAD START III: A PROSPECTIVE MULTINATIONAL PROTOCOL FOR NEWLY DIAGNOSED CNS EMBRYONAL TUMORS (MEDULLOBLASTOMA AND OTHER PRIMITIVE NEUROECTODERMAL TUMORS [PNET]) OF YOUNG CHILDREN WITH AN IRRADIATION-AVOIDING STRATEGY.**

FIRST REPORT OF RESPONSE TO AND OUTCOME OF INDUCTION CHEMOTHERAPY

Jonathan L. Finlay1, Kelley Haley2, Girish Dhall3, Sharon Gardner1, Jeffrey Allen1, Albert Cornelius1, Randy Olsheski1, James Garvin1, Kamesh Pradhan1, Michael Ertl4, Stewart Goldman5, Mark Atlas6, Stephen Thompson7, Andreas Fritt3, Juliette Hukin1, Melanie Comito1, Salvatore Bertolone1, Joseph Torkildson1, Michael Joyce1, Christopher Moertel14, John Letteino15, Gloria Kenedi16, Andrew Walter15, Lingyun Ji14, and Richard Spout2; Children's Hospital Los Angeles; *Children's Hospital Los Angeles, Los Angeles; †New York University Medical Center, New York; DeVos Children's Hospital, Grand Rapids; Columbus Children's Hospital, Columbus; Columbia Children's Hospital, New York; Ryley Children's Hospital, Indianapolis; Phoenix Children's Hospital, Phoenix; Children’s Memorial Hospital, Chicago; ‡Schneider Children’s Hospital, New Hyde Park; §Hackensack University Medical Center, Hackensack; †University Children’s Hospital, Basel; ¶Children’s Hospital, Vancouver; ¶Milton S. Hershey Medical Center, Hershey; ¶Kosair Children’s Hospital, Louisville; ¶Children’s Hospital of Oakland, Oakland; ¶Nemours Children’s Clinic & Wolfson Children’s Hospital, Jacksonville; ¶University of Minnesota Amplatz Children’s Hospital, Minneapolis; ¶Rainbow Babies & Children’s Hospital, Cleveland; ¶SUNY Upstate Medical University, Syracuse; ¶Alfred I. Dupont Hospital, Wilmington

PURPOSE: To improve survival and quality of life for young children newly diagnosed with medulloblastoma and other primitive neuroectodermal tumors (PNET). METHODS: Between April 2003 and December 2009, 144 children who had been newly diagnosed with medulloblastoma (n = 93) and other central nervous system (CNS) PNETs (n = 51) were enrolled among the 41 participating institutions. All patients were to receive five induction cycles (vincristine, cisplatin, cyclophosphamide, etoposide, and high dose methotrexate in cycles 1, 3, and 5; vincristine, cyclophosphamide, oral etoposide, and temorolomide in cycles 2 and 4) followed by (in children without tumor progression) consolidation with myeloablative chemotherapy (thiotepa, carboplatin, and etoposide) rescued with autologous hematopoietic cells. The initial Induction Regimen D was replaced halfway through the study by Regimen D2, in which cyclophosphamide and etoposide were eliminated to decrease toxicities.
RESULTS: Ongoing pathology review revealed that, of 93 institutionally diagnosed medulloblastoma cases, 28 (30%) were nodular/desmoplastic and 11 (12%) were diffuse anaplastic disease. The extent of resection in localized intracranial (IC) tumors based upon magnetic resonance (MR) imaging was gross total (R0) in 24/39 (62%), Disseminated disease (M1-3) was reported in 52/91 (57%). Among other PNET cases, the extent of resection in M0 patients was R0 in 14/25 (56%); M1-3 was reported in 25/50 (50%). Among medulloblastoma, the response to induction was: Continuing Complete Response (CCR) in 20/22 (92%), Complete Response (CR) in 25/92 (27%), <CR in 26/92 (28%), Progressive Disease (PD) in 19/92 (21%), Toxic Death (TD) in 2/92 (2%), and Not Yet Evaluable in 1/92 (1%). In M0 PNET cases, the induction in 10/50 (20%), CR in 8/50 (16%), <CR in 9/50 (18%), PD in 20/50 (40%), TD in 3/50 (6%), and pending in 1. Of medulloblastoma and other PNET patients, 67/93 (72%) and 27/50 (54%), respectively, proceeded to consolidation. CONCLUSIONS: Similar induction response rates were observed in Regimens B and D2. A higher than expected proportion of Head Start III medulloblastoma/other PNET patients had R1 and/or M1-3 disease, and/or diffuse anaplastic histology. Nevertheless, the responses to induction chemotherapy and the proportion of patients who proceeded to myeloablative chemotherapy are consistent with prior Head Start studies.

OT-05. A PILOT STUDY OF BEVACIZUMAB-BASED THERAPY IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMAS AND DIFFUSE INTRINSIC PONTINE GLIOMAS

Kathleen Dorris, Lars Wagner, Trent Hummel, Rachel Drissi, Lili Miles, James Leach, Lionel Chow, Rebecca Turner, Marsha N. Gragert, David Pruitt, Mary Sutton, John Benenam, Kerry Crane, and Maryam Fouladi; Cincinnati Children’s Hospital Medical Center

BACKGROUND: Outcomes for children with high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) remain poor. The combination of bevacizumab and irinotecan is commonly used for adults with recurrent HGG, and ongoing trials are now investigating bevacizumab as a radiosensitizer for adults newly diagnosed with HGG. The safety and feasibility of this approach in the pediatric population has not yet been reported. METHODS: An institutional pilot study of a bevacizumab-based regimen in children and young adults (ages, 3–29 years) with newly diagnosed HGG or DIPG was initiated. For the HGG stratum, chemoradiotherapy consisted of vincristine (10 mg/m2), doxorubicin (10 mg/m2), and procarbazine (150 mg/m2) orally daily for 14 days; a 21-day cycle was administered, while bevacizumab was administered at a dose of 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 of the cycle. A total of 37 patients were treated: 16/37 (43%) had received prior bevacizumab. Treatment was well tolerated: ≥ grade 3 hematologic toxicities occurred in 12/37 (32.4%) patients and consisted mainly of fatigue (5/37; 13.5%) and neutropenia (2/37; 5.4%); ≥ grade 3 hematologic toxicity occurred in 16/37 (43.2%) patients and consisted of thrombocytopenia (13/37; 35.1%), lymphopenia (2/37; 5.4%) and neutropenia (2/37; 5.4%). An interim efficacy analysis was conducted after 34 patients were enrolled and followed for 6 months. The trial failed to meet the predetermined interim analysis efficacy rule with 0/34 patients being progression-free at 6 months. Only 1 patient achieved a partial response according to the MacDonald criteria. The median time to progression (TPP) for all patients was 1.39 months (range, 0.5–5.6 months). Patients who had received prior bevacizumab therapy had a median TPP of 1.29 months versus 1.72 months for patients who had not received prior bevacizumab. Median overall survival (OS) was 2.4 months. Based on the results of this Phase II study, further evaluation of the vorinostat/bevacizumab combination in GBM patients is not recommended.

OT-06. PHASE II TRIAL OF VORINOSTAT IN COMBINATION WITH BORTEZOMIB IN RECURRENT GLOBLASTOMA MULTIFORME: A NORTH CENTRAL CANCER TREATMENT GROUP STUDY

Barrett T. Friday1, Jan Buckner2, S. Keith Anderson2, Caterina Giannini2, John Kugler1, Miroslaw Mazurczak4, Patrick Flynn1, Howard Gross3, Eduard Pajon1, Kurt Jacek1, and Evanthia Galani1; 1Mayo Clinic Cancer Center; 2Mayo Clinic; 3Loma Linda Cancer Center; 4Mayo Clinic (VA); 5SMD Cancer Center; 6Loma Linda University; 7SMD Cancer Center; 8Mayo Clinic; 9Illinois CancerCare; 10Souix Valley Clinic Oncology; 11Mayo Clinic; 12Children’s Hospital & Oncology of Dayton Inc; 13Colorado Cancer Research Program

Histone deacetylase (HDAC) inhibitor vorinostat has shown evidence of modest single-agent activity in glioblastoma multiforme (GBM). In preclinical studies, we have demonstrated significant synergistic cytotoxicity between HDAC inhibitors and proteasome inhibitors in GBM cell lines. We therefore conducted a Phase II trial to evaluate the efficacy of vorinostat in combination with the proteasome inhibitor bortezomib in patients with recurrent GBM. Patients who had received one or fewer regimens for progressive disease were eligible to participate; 6-month progression-free survival (PFS6) was the primary endpoint. Vorinostat was administered at a dose of 50 mg/m2 intravenously on days 1, 4, 8, and 11 of the cycle. A total of 37 patients were treated: 16/37 (43%) had received prior bevacizumab. Treatment was well tolerated: ≥ grade 3 nonhematologic toxicities occurred in 12/37 (32.4%) patients and consisted mainly of fatigue (5/37; 13.5%) and neutropenia (2/37; 5.4%). An interim efficacy analysis was conducted after 34 patients were enrolled and followed for 6 months. The trial failed to meet the predetermined interim analysis efficacy rule with 0/34 patients being progression-free at 6 months. Only 1 patient achieved a partial response according to the MacDonald criteria. The median time to progression (TPP) for all patients was 1.39 months (range, 0.5–5.6 months). Patients who had received prior bevacizumab therapy had a median TPP of 1.29 months versus 1.72 months for patients who had not received prior bevacizumab. Median overall survival (OS) was 2.4 months. Based on the results of this Phase II study, further evaluation of the vorinostat/bortezomib combination in GBM patients is not recommended.

OT-07. PHASE II STUDY OF BI-WEEKLY TEMOZOLOMIDE PLUS BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT GLOBLASTOMA MULTIFORME

Michael A. Badruddoq1, Marjorie A. Pazzi1, Baldassarre Stea2, Patricia Lefferts3, Nancy Contreras1, Maria Bishop2, Joachim Seeger1, Raymond Carmody2, Naomi Rance2, Marco Marsella2, Kurt Schroeder1, and Abbay Sanan2; Center for Neurosciences, 1University of Arizona; 2St. Mary’s Hospital

BACKGROUND: The use of single-agent bevacizumab (BEV) improves the outcomes of patients with recurrent glioblastoma multiforme (GBM) following prior therapy. Metronomic/dose-dense temozolomide (TMZ) has been combined with BEV in the treatment of recurrent GBM; however, the optimal dosing of TMZ has not been defined. The combination of BEV and metronomic TMZ may not increase survival to levels above that found with the use of BEV alone. The purpose of this study was to determine the 6-month progression-free survival of patients with recurrent GBM treated with BEV plus bi-weekly dosing of TMZ. Secondary endpoints included radiographic response, evaluation of toxicity, analysis of tumor DNA (MGMT and a 9-gene assay), and functional assessment of cancer therapy for brain tumors (FACT-B). METHODS: This clinical trial is ongoing, with an accrual goal of 30 subjects. Patients are treated with 10-mg/kg BEV in combination with 100-mg/m2 TMZ every 2 weeks; this regimen is continued until tumor progression or unacceptable toxicity occurs. Complete patient evaluations are conducted every 4 weeks and magnetic resonance imaging (MRI) scans are done every 8 weeks. FACT-B questionnaires are completed every 8 weeks. RESULTS: Preliminary data is presented here. Nine patients have been accrued thus far and 5 patients have been actively enrolled; 8 patients have shown a partial radiographic response and 1 patient was a nonresponder. Methylation of the MGMT gene was NOT detected in 7 subjects and is pending in the remaining 2. Grade 3 toxicities have included: encephalopathy (epileptic), deep vein thromboses, pulmonary emboli, and fatigue. There was one grade 5 CNS hemorrhage in a patient who had discontinued the study due to tumor progression. CONCLUSIONS: The combination of BEV and TMZ given bi-monthly is well-tolerated and may have efficacy in the treatment of recurrent GBM. Added safety and efficacy data will be reported as this Phase II study progresses.

OT-08. OBJECTIVE RESPONSE RATE OF UNRESECTABLE BENIGN MENINGIOMA TO HYDROXYUREA: SOUTHWEST ONCOLOGY GROUP PHASE II TRIAL S9811

Lode J. Swinnen1, Cathryn Rankin2, Elisabeth J. Rushing3, Laura D. Johnson4, Theodore K. Tomaszewski5, David R. Luckett2, J. Mark Claudio1, Kirsten A. Kooch3, 1University of Southern California; 2Southwest Oncology Group; 3University of Alabama at Birmingham; 4Southwest Oncology Group Statistical Center; 5Armed Forces Institute of Pathology; 6Wayne State University

BACKGROUND: An effective drug would be valuable for patients with benign meningioma that is no longer amenable to resection or irradiation.
Objective responses have been reported with long-term hydroxyurea (HU) therapy, and activity has been demonstrated in benign meningioma primary explant cultures. The Southwest Oncology Group S9811 Phase II trial was designed to estimate the objective response rate of unresectable benign meningioma to that same HU regimen. METHODS: Inclusion criteria included having unsectectable, measurable, histologically proven benign meningioma; progressive tumor or progressive neurologic deficit at >1 year after radiation therapy; having had no prior cytotoxic chemotherapy; being age >18 years; having adequate hematologic reserve; and PS 0–2. 20–mg/kg/day HU was given orally for up to 2 years in the absence of progressive disease. Single-stage accrual of 38 patients would have allowed detection of a 5% null hypothesis response probability vs. 20% observed improvement; 28 eligible patients actually accrued provide 81% power. RESULTS: Twenty-nine patients were accrued onto the study over 7 years, with study closure due to slow accrual. One ineligible patient response assessment showed complete response + partial response in 0% (95% CI, 0%–12%); stable disease in 71% (95% CI, 51%–87%); progressive disease in 21% (95% CI, 8%–41%); and undetermined response in 7%. Median progression-free survival (PFS) was 27 months (95% CI, 12–80 months); 3-year PFS was 43% (95% CI, 25%–61%). Median overall survival (OS) is not yet available, but the 3-year OS was 79% (95% CI, 63%–94%). Seven patients were removed from the study because of toxicity (5/7 had hematotoxic toxicity). Toxicity was primarily hematologic: 11/28 (39%) had grade 3 and 2/28 (11%) had grade 4. Grade 3 nonhematologic toxicity was seen in 7/28 (25%). patients. CONCLUSIONS: Chronic HU therapy may provide an acceptable therapeutic option for patients with unresectable benign meningioma, with an objective response rate of <12%. Whether the stable disease found in 71% of patients was the result of treatment cannot be determined from this Phase II study design.

OT-09. PHASE II STUDY OF DOSE-INTENSE TEMOZOLOMIDE IN RECURRENT GliOBlastoma
Andrew D. Norden1, Glenn Lesser2, Samantha N. Hammond1, Jan Drappatz1, Howard A. Fine3, Howard A. Finkelstein4, John A. Butman5, and Patrick Y. Wen1; 1Dana-Farber Cancer Institute; 2Cedars-Sinai Medical Center; 3Massachusetts General Hospital Cancer Center; 4Wake Forest University Comprehensive Cancer Center; 5Northwestern University Comprehensive Cancer Center; 6Memorial Sloan-Kettering Cancer Center

BACKGROUND: Survival among patients with glioblastoma (GBM) is poor, and the majority of patients relapse within 1 year. Among patients who progress on the standard schedule of temozolomide (150–200 mg/m²/day for 5 consecutive days every 28 days), the optimal therapy is unknown. Resistance to temozolomide is partially mediated by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). Since MGMT may be depleted by prolonged temozolomide administration, there is interest in whether dose-intense schedules of temozolomide can overcome MGMT-mediated resistance in patients with recurrent GBM. METHODS: This is a Phase 2, single-arm, multicenter study of temozolomide (75–100 mg/m²/day for 21 days of a 28-day cycle for up to 12 cycles). To be eligible, patients had to have historically confirmed GBM in first recurrence following standard therapy, including at least 2 cycles of adjuvant temozolomide dosed in the standard fashion. The primary endpoint was 6-month progression-free survival. A planned subgroup analysis will compare participants whose tumors recurred during adjuvant temozolomide therapy to those whose tumors recurred after completion of the adjuvant temozolomide regimen. RESULTS: Forty-one participants have been accrued to date. Overall, the regimen has been well tolerated, with toxicity comparable to the standard temozolomide dosing regimen. Accrual continues, and updated results, including response, survival data, and correlation of clinical outcomes with tumor MGMT status, will be presented. CONCLUSIONS: Dose-intense temozolomide on a 21/28 day schedule is a safe regimen for patients with GBM in first recurrence. Updated efficacy results will be presented.

OT-10. PHASE II STUDY OF MONTHLY PASIREOTIDE LAR (Som230c) FOR RECURRENT OR PROGRESSIVE MENINGIOMA
Samantha N. Hammond1, Andrew D. Norden1, Jan Drappatz1, Surasak Phuphanich2, David Redmond3, Eric T. Wong1, Scott R. Plotkin4, Glenn Lesser5, Akiva Mintz4, Jeffrey J. Raizer5, Tracy T. Batchelor1, Eudocia C. Quant1, Rameen Beroukhim1, Thomas J. Kaley6, Abigail Ciampa7, Sandra Johnston8, Karyl D. Mbata7, Myrna R. Rosenfeld9, and Patrick Y. Wen1; 1Dana-Farber Cancer Institute; 2Wake Forest University Comprehensive Cancer Center; 3Dartmouth-Hitchcock Norris Cotton Cancer Center; 4Massachusetts General Hospital Cancer Center; 5University of Pennsylvania Comprehensive Cancer Center; 6Memorial Sloan-Kettering Cancer Center; 7Northwestern University Comprehensive Cancer Center; 8Memorial Sloan-Kettering Cancer Center; 9University Comprehensive Cancer Center; 10Northwestern University Comprehensive Cancer Center; 11University of Washington, Fred Hutchinson Research Center

BACKGROUND: Patients with recurrent meningiomas who have exhausted surgical and radiation options have limited remaining treatment choices. Despite interest in treating such patients with cytotoxic chemotherapies and targeted molecular agents, no effective cytotoxic therapies exist. Somatostatin receptors are expressed in nearly 90% of meningiomas, and somatostatin effectively inhibits meningioma cell growth in vitro. In a pilot study, 16 patients with recurrent meningiomas were treated with a sustained-release somatostatin preparation (Chamberlain et al. Neurology, 2007; 69:969–73); nearly one-third of patients achieved partial response, toxicity was minimal, and the 6-month progression-free survival rate (PFS6) was 44%. Pasireotide LAR (Som230c) is a long-acting somatostatin analog that has higher binding affinity for most somatostatin receptor subtypes than octreotide. Like octreotide, pasireotide is well-tolerated in most patients. Results for the OT-11 segment presented here are preliminary.

METHODS: This is a Phase 2, single-arm, multicenter study of temozolomide. Treatment cycles are 28 days in length, and treatment continues until progressive disease or unacceptable toxicity. Patients are examined at the beginning of cycles 1–3, at the midpoints of cycles 1 and 2, and then at the beginning of cycle 4. Restaging magnetic resonance imaging (MRI) scans are performed every 3 cycles, and response is assessed using the Macdonald criteria. RESULTS: Twenty patients have been accrued, 17 (85%) of whom have atypical/ malignant meningiomas. Response results and survival data will be presented.

CONCLUSIONS: Pasireotide LAR is a well-tolerated somatostatin analog that is under investigation for heavily pretreated recurrent meningioma. Efficacy results have yet to be determined.

OT-11. BENDAMUSTINE FOR RECURRENT GLiOBlastoma
Marc C. Chamberlain1, Carrie Graham2, Macie Murgula2, and Sandra Johnston3; University of Washington, Fred Hutchinson Research Center

BACKGROUND: The treatment of recurrent glioblastoma (GBM) remains challenging, notwithstanding the recent approval of bevacizumab for this indication. Bendamustine has a bifunctional mechanism of action, penetrates the CNS, and does not show cross-resistance to other alkylators. METHODS: In a single-institution, open-label, prospective Phase 2 trial, patients with recurrent GBM were treated with bendamustine (100 mg/m²/day administered intravenously for 2 consecutive days every 4 weeks). All patients previously had been treated with surgery, temozolomide, and radiation therapy. The primary study endpoint was 6-month progression-free survival (PFS6) and the study design was a Simon 2-step, such that if 3 or more of the initial cohort of 16 patients manifested PFS6, an additional 14 patients would be enrolled. Complete blood counts were obtained bimonthly, clinical evaluations were performed monthly, and brain imaging was performed every cycle. Treatment regimens were based upon Macdonald criteria. RESULTS: Sixteen patients (9 men; 7 women) entered onto trial with a median age of 53 years (range, 36–68) and median Karnofsky performance status of 90 (range, 70–100). Ten patients were treated at first relapse and 6 at second relapse (bevacizumab had failed 5 patients). A total of 17 cycles of bendamustine were administered, with a median of 1 (range, 1–6). Bendamustine-related toxicity was seen in 7 patients, lymphopenia in 5 (4 CTC grade 3; 1 grade 4), and thrombocytopenia in 2 (2 grade 3). Twelve patients died from disease progression, 3 patients alive and on alternative therapy, and 1 patient continues on study. The PFS6 was 6.25%. CONCLUSION: Bendamustine was reasonably well tolerated but failed to meet the study’s prespecified endpoint of a PFS6 of 19% and, consequently, does not appear to be active in adults with recurrent GBM.

OT-12. A PHASE II TRIAL OF SUNITINIB IN THE TREATMENT OF RECURRENT GLiOBlastoma (GBM)
Terry N. Kreis1, Patricia Smith2, Fabio Iwamoto3, Joohee Sul4, John A. Butman5, and Howard A. Fine; National Institutes of Health

While the response rate for bevacizumab (BEV) in patients with glioblas-
toma (GBM) is high relative to other salvage regimens, durable disease
control remains elusive for the majority of patients, possibly due to activation of angiogenic factors other than vascular endothelial growth factor (VEGF). Suniptinib is an orally available multitarget tyrosine kinase inhibitor of VEGFR, and c-KIT that down-regulates several angiogenic growth factors with high specificity to EGFR.

We designed a Phase II trial for recurrent GBM, stratified by prior exposure to BEV, in order to assess the safety and efficacy of 37.3-mg suniptinib administered on a continuous daily schedule. The primary endpoint for both cohorts was 6-month progression-free survival. Patients who progressed on BEV were eligible if their last treatment was ≥6 weeks before study entry. Patients treated with enzyme-inducing antiepileptics, prior non-BEV VEGF-directed therapies, concurrent anticoagulation therapy, and other significant cardiovascular conditions were not eligible for the study. Radiologic and clinical evaluations were performed every 4 weeks. FDG-PET scans were evaluated at baseline and end of the first 4-week cycle as a correlative study. Twenty-eight patients have been enrolled to the BEV-resistant arm and 21 patients have been enrolled to the BEV-naive arm. Applying modified Macdonald criteria, only one patient has achieved a partial response in the BEV-naive arm. Four additional patients (2 BEV-naive and 2 BEV-resistant) had a significant reduction in contrast enhancement but did not meet the criteria for partial response.

No patients have reached 6-month progression-free survival. Updated response, toxicity, and survival data will be presented. Preliminary results from this trial indicate that while suniptinib has activity in terms of radiographic response for some patients, disease control may be poor for patients with recurrent GBM who have had prior exposure to bevacizumab. Results in patients who are BEV-naive will be presented by the time of the meeting.

OT-13. CURRENT STATUS OF A PHASE III TRIAL OF NIMOTUZUMAB (ANTI-EGFR) IN NEWLY DIAGNOSED GLIOBLASTOMA

Manfred Westphal,1 Oliver Heese,2 M. Warmuth-Metz,3 Torsten Pietsch,4 Uwe Schlegel,5 Jörg-Christian Tonn6, Johannes Schramm7, Volker Seifert11, K. Geletneky12, D. Reuter13, and Ferdinand Bach13; 1UK Neurosurgery, University Kiel; 2Neurosurgery, University Frankfurt; 3Institut für Zellbiologie, Freie Universität Berlin, Berlin; 4Neurosurgery, University Hamburg; 5Neurosurgery, University Münster; 6Neurosurgery, University of Regensburg; 7Neurosurgery, University of Tübingen; 8Neurosurgery, University Dresden; 9Neurosurgery, University Leipzig; 10Neurosurgery, University of Erlangen; 11Neurosurgery, University of Munich; 12Neurosurgery, University of Tübingen; 13Neurosurgery, UK Heidelberg; 14OncoScience AG, Wedel

RATIONALE: Epidermal growth factor receptor (EGFR) has been shown to be relevant to glioma by numerous approaches. It is a drug target for small-molecule tyrosine kinase inhibitors, targeted toxins, and monoclonal antibodies. Within the CNS, it has exquisite selectivity for high-grade glioma cells. Supported by promising preclinical and early clinical findings, we tested the therapeutic effect of a monoclonal antibody against EGFR (nimotuzumab) that had a lower affinity than cetuximab and that bound more specifically to highly overexpressing cells. METHODS: Nimotuzumab (OSAG-101) was tested in an open-label, randomized, multi-center Phase III trial in patients with newly diagnosed glioblastoma. OSAG-101 was administered by intravenous infusion (2 weekly infusions of 400 mg) in addition to the current standard radiochemotherapy, followed by biweekly infusions of 400 mg thereafter until progression. Patients with histologically confirmed glioblastoma were included and stratified for recurrence status. Patients under the age of 18 years and over 70 years were excluded. The primary endpoint was time to progression as determined by tumor size at baseline by CT/MRI. All patients were scheduled to receive a median of 6 cycles of therapy. Patients were eligible for enrollment with a Karnovsky score of 70 to 100. RESULTS: Between August 2008 and March 2010, the targeted total study population of 313 patients was enrolled at 10 sites. A prespecified analysis of the first cohort of 75 patients who had a minimum follow-up of 12 months showed no specific toxicity of nimotuzumab and an unsuspicious safety profile; neither rash, conjunctivitis, nor mucositis were reported. It is too early to determine the treatment efficacy in the overall group; however, molecular markers such as MGMT status and EGFR expression levels are currently being determined. CONCLUSION: The intravenous administration of OSAG-101 for newly diagnosed glioblastoma has been proven safe and free of additional toxicity when added to standard radiochemotherapy. The interim analysis has not been able to determine efficacy yet without correlation to molecular markers.

OT-14. PHASE II TRIAL OF CONTINUOUS LOW-DOSE TEMOZOLOMIDE (TMZ) FOR PATIENTS WITH RECURRENT MALIGNANT GliOMA (MG) WITH AND WITHOUT PRIOR EXPOSURE TO BEVACIZUMAB (BEV)

Mustafa Khasraw, Lauren E. Abrey, Andrew B. Lassman, Adilia Harmigo, Craig Nolan, Igor T. Gavrilovic, Ingo K. Mellinghoff, Anne S. Reiner, Lisa DeAngelis, and Antonio M. Omuoro; MSKCC

BACKGROUND: Metronomic TMZ schedules have been proposed as salvage therapy for recurrent malignant glioma (MG) with the goal of targeting O-6-methylguanine-DNA-methyltransferase (MGMT). METHODS: In this prospective Phase II study, patients with recurrent/progressive MG were treated with daily TMZ (50 mg/m²) until progression. A Simon 2-stage design was used; the primary endpoint was 6-month progression-free survival (PFS) (promising: 20%, nonpromising: 3%, alpha = 0.1, beta = 0.1, N = 37 planned GBM). Ten additional cases of recurrent anaplastic astrocytomas (AA) or oligodendrogliomas (AO) were included for exploratory analysis. RESULTS: Forty-seven patients were enrolled (glioblastoma [GBM]: 37; AA: 6; AO: 4; median age: 56 years; median KPS: 80; 16 were women). The MGMT promoter was methylated in 5 patients, unmethylated in 37. 5 patients had prior exposure to BEV. Median PFS was 3 (CI, 1–6); median overall survival (OS): 7 months (CI, 4–9); objective response rate: 6%. GBM patients with prior BEV exposure fared worse than GBM patients with no BEV exposure (6-month PFS: 12% vs 48%, P = 0.007; median OS: 5 months vs 11 months). In AOs, 6-month PFS was 30% and median OS was 16 months (CI, 7–30). There was a trend towards shorter PFS in unmethylated patients (P = 0.06). CONCLUSIONS: The regimen was well tolerated in this heavily pretreated population. The primary endpoint was met, indicating that this treatment deserves further investigation. Although the increase in treatment efficacy in the overall GBM population was modest, results in non-BEV failures were particularly encouraging and comparable to BEV. Results in BEV failures are difficult to interpret due to lack of historic controls. This study highlights the need for stratification according to previous BEV exposure and for new historic controls for trials of recurrent MG.

OT-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 (ANP) IN ADULT PATIENTS WITH RECURRENT MIXED GLIOMAS

Stanislaw R. Burzynski, Robert A. Weaver, Tomasz J. Janicki, Gregory S. Burzynski, Barbara Szymkowska, and Sherill S. Acelar; Burzynski Clinic of Natural Oncology

The purpose of this study was to evaluate the efficacy and toxicity of anti-neoplastic agents A10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas. Thirteen of 20 patients enrolled were evaluable; 7 patients could not be evaluated due to an inadequate duration of treatment and lack of follow-up magnetic resonance imaging (MRI) scans. Nine were women and 9 men. The median age was 38 (range, 29–54) and the median KPS score at baseline was 70 (range, 60–100). One patient had low-grade and twelve patients had high-grade mixed gliomas. All patients received chemotherapy, radiation therapy, and surgery prior to ANP, with the exception of one patient who received no chemotherapy or radiation therapy postsurgery. Patients received escalating doses of intravenous ANP six times daily. The median duration of treatment was 4.4 months; the median of average dosages of A10 was 6.0 g/kg/day and of AS2-1 was 0.3 g/kg/day. ANP was well tolerated, with the most common side effects being urinary frequency, hypernatremia, dysgeusia, myalgias, nausea, and hypersensitivity. Serious (grade 3) toxicity (urinary frequency) was observed in only 1 patient and there were no grade 4 toxicities. Response to ANP was monitored by MRIs of the brain. The responses were as follows: complete response, 23%; partial response, 8%; stable disease, 23%; and progressive disease, 46%. Progression-free survivals (PFS) at 1, 2, and 5 years were 31%, 23%, and 8%, respectively. Overall survivals (OS) from diagnosis and from start of treatment at 1, 2, and 5 years were 92% and 54%, 85% and 8%, and 35% and 4%, respectively. The preliminary results of our small study of adults with recurrent mixed gliomas revealed ANP to be very effective in resolving or stabilizing disease in more than 50% of treated patients as well as encouraging PFS and OS with minimal toxicity.
OT-16. LONG-TERM IMAGING DATA FROM HCRRF PHASE III STUDIES DEMONSTRATE STABILITY OF CEREBRAL TUMORS AND PERITUMORAL EDEMA

Lazlo L. Mechtler1, Patrick C. O'Connor2, and Henk-André Kroon3; 1Dent Neurologic Institute; 2Celtic Pharma

A subgroup of 98 patients with cerebral tumors (GBM, n = 46; other primary brain tumors, n = 33; cerebral metastases, n = 19) who received HCRRF through all Phase III studies (NTI 302, 303, and 3091) were retrospectively enrolled in a magnetic resonance imaging (MRI) study to evaluate the change from baseline of tumor volume (TV) and peritumoral brain edema (PBE). The TV was measured at the largest dimension on the postcontrast T1 weighted image. PBE was measured at the largest area on FLAIR imaging at each time point. Each was compared to the first available MRI or computed tomography (CT) data set. The quantitative assessments of changes in the TV and PBE regions were performed according to World Health Organization (WHO) criteria: Progressive Disease (PD) = +25%–+100% or more; Stable Disease = +24%–50%; and Responder (R) = -100%–100%. Patients could meet more than one criterion during the study. Stable disease was the maximum TV response in 72% of subjects. The mean duration of stable TV was 58% of the observation time (mean, 5.8 months), with PD 38% (mean, 3.7 months), and R 4% (mean, 2.2 months). These proportions were similar in the primary and metastatic-disease subgroups and in patients with GBM and other primary brain tumors. Stable PBE was noted in 78% of patients. The mean duration of stable PBE was 65% of the observation time (6.3 months), of PD was 29% (mean, 4.1 months) and of R was 6% (mean, 7.6 months). As with TV, the proportions were similar in the primary and metastatic-disease subgroups and in GBM. These findings are notable in that treatment with HCRRF was also associated with a concomitant 87.5% decrease in steroid requirements in study NTI0501. These findings are consistent with the postulated antiangiogenic mechanism of action of HCRRF on cerebral tumors.

OT-17. A PROSPECTIVE STUDY OF CONCURRENT CARBOPLATIN AND RADIATION THERAPY (CIRT) FOLLOWED BY ADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK MEDULLOBLASTOMA

Tushar Vora, Parma Kurkure, Brjesh Aroz, Tejpal Gupta, Vandana Dhamankar, Shipad Banavali, Aliasgar Mosyadi, Shridhar Epapi, Nikhil Merchant, and Rakshak Jalali; Tata Memorial Hospital

AIM: To assess the role of concurrent carboplatin and radiation therapy (CIRT) followed by adjuvant chemotherapy (AC) in patients with high-risk medulloblastoma (HRM) for improving event-free survival (EFS). METHODS: Newly-diagnosed 3- to 21-year-old HRM patients have been prospectively accrued since July 2004. Within 6 weeks of surgery, all patients underwent CIRT, including craniospinal radiation (CSL; 35 Gy/21#) with tumor bed boost (19.8 Gy/11#) with 35-mg/m2/day carboplatin 5 days a week for 15 dose (during 3 weeks of CSI), followed by 6 cycles of 4-weekly adjuvant chemotherapy (vinblastine, cisplatinum, and cyclophosphamide) beginning 4 weeks post-CIRT. RESULTS: 26 patients have been accrued. Median age was 8.5 years (range, 4–17 yrs). M:F ratio was 3:1. M stage: 62% were M0, 3.8% each were M1 and M2, and 30.8% were M3. At the end of CIRT, 23 (88.5%) are in complete response (CR), 2 (7.7%) are in partial response (PR), 1 (3.8%) has radiologic stable disease, and none of the patients has had progression on CIRT. 26 patients were started on AC, 19 of whom have completed treatment. Two patients are still on AC, 2 (7.7%) who had progressive disease, 2 (7.7%) died from toxicity, and in 1 (3.8%), treatment was discontinued because of toxicity. At a median follow-up duration of 30 months (range, 2–51 months), 17/26 are in CR (EFS - 65%) and 5/26 (19.2%) patients have relapsed/progressive disease. During treatment, grade III-IV anemia was observed in 17%, neutropenia in 54%, and thrombocytopenia in 26%, 92% of patients had anorexia, 100% had nausea/vomiting, 71% developed mucositis, 70% had grade II-II radiation dermatitis, and 94% had alopecia. 21% of patients had febrile neutropenia and 57% required G-CSF support. During adjuvant chemotherapy, hematologic toxicity (grade III-IV) was observed in 85% of patients. CONCLUSION: Concurrent CIRT followed by AC is feasible with manageable toxicities for children presenting with HRM and the encouraging EFS of 65% may translate into higher cure rates.

OT-18. A PHASE II TRIAL WITH BEVACIZUMAB AND IRINOTECAN FOR PATIENTS WITH PRIMARY BRAIN TUMORS AND PROGRESSION AFTER STANDARD THERAPY

Soren Mørk, Steen Grønne Hjort, Hendrik Schulte1, Mats Holmberg4, Morten S. Sorensen1, Hans S. Poulsen1, and Ulrik Lassen1; 1Copenhagen University Hospital, Righospitalet; 2Odense University Hospital; 3Aarhus University Hospital; 4Aalborg University Hospital

INTRODUCTION: The combination of irinotecan and bevacizumab has shown efficacy in the treatment of recurrent brain tumors. A multicenter, phase II, nonrandomized study of 77 patients with various recurrent brain tumors, was carried out. Primary endpoints were progression-free survival (PFS) and response rate. We included 77 patients with performance statuses of 0–2 with recurrent primary brain tumors. Diagnoses were glioblastoma multiforme (n = 32), anaplastic astrocytoma of World Health Organization (WHO) grade 3 (n = 13), anaplastic oligodendroglioma of WHO grade 3 (n = 8), anaplastic oligoastrocytoma of WHO grade 3 (n = 5), astrocytoma of WHO grade 2 (n = 8), oligoastrocytoma of WHO grade 2 (n = 2), ependymoma of WHO grade 3 (n = 2), gliosarcoma of WHO grade 3 (n = 2), medulloblastoma of WHO grade 4 (n = 1), prolactinoma (n = 1), Schwannoma of WHO grade 4 (n = 1), and meningioma (n = 1). 95% of patients had received prior chemotherapy.

MATERIALS AND METHODS: Patients were treated with 10-mg/kg intravenous bevacizumab and 125/340-mg/m2 irinotecan every 14 days (2 treatments = 1 cycle). Evaluation was carried out every 8 weeks using magnetic resonance imaging (MRI) and McDonald response criteria. Treatment was continued until disease progression or death. RESULTS: Patients received a median of 4.5 cycles. Best responses to treatment for glioblastoma were 0% CR, 26% PR, disease control and 70% SD. For WHO grade 3 tumors, 18% CR, 41% PR, and 41% SD. For glioma, the best responses were 17% CR, 0% PR, and 83% SD. Median PFS for all patients was 23 weeks and for glioblastomas was 26 weeks. Side effects included mild (grade 1) fatigue and nausea. Seven patients experienced serious (grade 2) thrombocytopenic or bleeding events. DISCUSSION AND CONCLUSION: The combination of bevacizumab and irinotecan is well tolerated and moderately efficacious in glioblastoma and other recurrent brain tumors. A majority of patients achieved at least disease stabilization with this treatment. The median PFS of 23 weeks compares favorably with historic results.

Abstracts
OT-20. PACLIATAXEL POLIGLUMEX (PPX), TEMODAR (TMZ), AND RADIATION (RT) FOR NEWLY DIAGNOSED HIGH-GRADE GLIOMAS: A BROWN UNIVERSITY ONCOLOGY GROUP PHASE II STUDY

Surya Jayapalan 1, Maria Constantinoiu 1, Devon Evans 2, Heinrich Elinzon 1, Brigid O’Connor 1, M. Yakub Puthawala 1, Mark Goldman 1, Adetukunbo Oyelese, Dea Cicelo, Thomas Dipetrillo, and Howard Safran 1
1Rhode Island Hospital; 2Maine Center for Cancer Medicine (MCCM)

BACKGROUND: The conjugation of paclitaxel to a poly-L-glutamic acid polymer forms PPX, which has an increased radiation enhancement factor. In esophageal adenocarcinoma, PPX and radiation (RT) achieved a pathologic complete response of 30% (Safran, ASCO 2010). The primary objective of this study was to determine the safety of PPX with standard TMZ and RT for patients with high-grade gliomas. METHODS: Patients received weekly PPX 50 mg/m2 and daily TMZ 75 mg/m2 for 6 weeks with concomitant RT (200 cGy, 5 d/wk for a total dose of 60 Gy). Adjuvant chemotherapy with TMZ (200 mg/m2 x 5 x 80 cGy), repeated every 28 days, was started 1 month afterward and continued until evidence of disease progression. RESULTS: The study has accrued 24 out of 25 planned patients, 13 patients had glioblastomas (GBMs), 21 patients completed radiation (3 are ongoing). Due to thrombocytopenia, 2 patients received only 4 weeks of TMZ/PPX and 3 patients received 5 weeks. The main toxicity was myelosuppression: 3/14 (21.4%) patients had an asymptomatic grade IV thrombocytopenia. The Data Safety Monitoring Group recommended the PPX dose to 40 mg/m2/week and an additional 2/10 (20%) patients developed an asymptomatic grade 4 thrombocytopenia; 1 patient was also on aspirin/clopidogrel. Other hematologic grade 3/4 toxicities were: grade III thrombocytopenia (1/24, 4.2%), neutropenia (1/24, 4.2%), and lymphopenia (1/24, 4.2%). Treatment related nonhematologic grade 3/4 toxicities were: dehydration, anorexia, upper extremity pain, weakness, and elevated alkaline phosphatase. The median duration of follow-up was 7.75 months (range, 1–16 months). Fifteen patients were enrolled in the protocol for at least 6 months and 10 of them (67.7%) were progression free at 6 months. CONCLUSION: PPX with TMZ and concurrent radiation is an easily administered regimen for high-grade gliomas. The hematologic toxicities were asymptomatic and the 6-month progression-free survival (PFS) rate of 67.7% is encouraging. Results will be updated.

OT-22. PHASE III SAPPHIRE STUDY IN HIGH-GRADE GLIOMAS: TARGETED THERAPY WITH TGF-BETA INHIBITOR TRABEDERSEN BASED ON RESULTS OF A RANDOMIZED PHASE IIb STUDY

Ulrich Bogdahn 1, Gunther Stockhammer 2, Asok Kumar Mahapatra 1, Neelam K. Venkataramana 4, Victor Emeljanovich Oliushine 5, Valery Evgenyevich Parfenov 6, Irina Evgenievna Poveremnova 7, Peter Haut 8, Post-Jochimczak 9, Hubert Heinrichs 8, and Karl-Hermann Schlingensiepen 8
1University of Regensburg, Department of Neurology; 2University of Innsbruck, Department of Neurology; 3Sanjay Gandhi Post-Graduate Institute of Medical Sciences; 4Manipal Hospital, Manipal Institute for Neurological Disorders; 5Polish Neurosurgery Research Institute St. Petersburg; 6Military Medical Academy St. Petersburg; 7Samara Medical Hospital; 8University of Regensburg, Department of Neurology, Regensburg; 9Antisense Pharma GmbH, Regensburg

INTRODUCTION: TGF-beta2 regulates key mechanisms of carcinogenesis, especially immunosuppression and metastasis. The antisense oligonucleotide trabedersen (AP 12009) is a TGF-beta2-specific inhibitor developed for the treatment of patients with highly malignant tumors such as recurrent or refractory high-grade glioma (HGG). METHODS: Clinical studies with trabedersen in HGG have included 3 phase I/II studies and one randomized, controlled, multinational dose-finding phase Ib study. These studies were performed in adult patients with recurrent/refractory high-grade glioma (at least one of the two doses of trabedersen: 150 mg/m2 or 300 mg/m2). The highest efficacy was observed in AA patients treated with 10-μM trabedersen. In this group, the 14-month progression rate was 16.7%, which was lower than seen with 80-μM trabedersen (40.0%, P = 0.1534) or chemotherapy (58.3%, P = 0.0032). The 10-μM trabedersen group also had a 3-fold longer duration of response and a clearly longer median survival than chemotherapy (39.1 vs. 21.7 months, ns). In addition, promising efficacy data were observed in GBM, especially in patients not older than 55 years with Karnofsky Performance Statuses (KPS)>80% at baseline, who had a 24-month survival rate of 40% in the 10-μM trabedersen group vs. 13% in the chemotherapy group. Trabedersen generally had a good tolerability and safety profile. CONCLUSIONS: Trabedersen treatment showed a clear clinical benefit in recurrent HGG. Based on the Phase Ib results, the pivotal Phase III SAPPHIRE study in patients with recurrent/refractory AA was started. Patient recruitment is ongoing. The primary endpoint is 2-year survival rate; secondary endpoints include overall survival, tumor response, quality of life, and safety.

OT-21. DETECTION OF TEMOZOLOMIDE AND MTIC IN BLOOD OF GLIOMA PATIENTS TREATED WITH TEMOZOLOMIDE

Mitsuhiro Anan, Momohayed Seyed Sadr, Jad Alshami, Carmen Sabau, Emed Seyed Sadr, Vincent Su, Marie-Christine Guisot, Amir Samani, and Rolando Del Maestro; MNI - McGill University

BACKGROUND: Glioblastoma patients are currently treated by surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ). TMZ is converted to monomethyl triazeno imidazole carboxamide (MTIC) in a physiological step, which is responsible for the methylation of the DNA genome adducts. We have completed a Phase II trial assessing the influence of neoadjuvant presurgical treatment of glioma patients with the administration of a daily dose of 75 mg/m2 of TMZ for 14 days prior to surgery. METHODS: Blood was drawn from patients at days 1 (control), 7, 14, 21, and 42. Surgery was performed on day 14 and TMZ was orally administered immediately before surgery. On the day of surgery, blood was drawn at 2, 4, 6, 8, 10, and 12 hours after TMZ administration (n = 7). Tumor and normal-tissue samples were collected from patients enrolled in the trial. We have evaluated plasma and tissue TMZ and MTIC levels in these samples. RESULTS: Plasma TMZ and MTIC levels peaked 2 hours after TMZ administration. Variable levels of TMZ and MTIC were observed in plasma samples, especially 2 hours after TMZ administration. A rapid decay of TMZ and MTIC levels was observed in all patients with no measurable detection 24 hours post-TMZ administration. We were unable to detect TMZ or MTIC in brain tumor (n = 28) and normal brain tissues (n = 5) resected 4 hours after TMZ administration. CONCLUSIONS: TMZ and MTIC plasma levels peaked 2 hours after TMZ administration and maximum variability in these levels was also observed at this time point. We were unable to detect TMZ and MTIC in brain tumor or normal brain tissues 4 hours after TMZ administration. These results suggest it may be more appropriate to assess TMZ-induced guanine N7 and O6 methylation as downstream targets of TMZ efficacy rather than tissue levels of TMZ and MTIC.

OT-23. CLINICAL TRIALS FOR MALIGNANT BRAIN TUMORS CONDUCTED BY JCOG-BRAIN TUMOR STUDY GROUP

Kazuma Kiyokawa1, Tatsuya Hamada2, Takasumi Kayama1, Toshihiko Wakabayashi2, and Ryo Nishikawa3; 1National Cancer Center Hospital; 2Nagoya University; 3National Cancer Center Research Institute

PURPOSE: A multi-institutional cooperative study group for brain tumors (JCOG-Brain Tumor Study Group) was organized and conducted Phase II/III studies in order to establish the standard therapy for malignant brain tumors. METHODS: The group consists of 32 neurosurgical institutions and has started clinical trials for malignant gliomas, metastatic brain tumors, and primary CNS lymphomas. These studies are supported by grants from the Ministry of Health, Labor, and Welfare, Japan. RESULTS: The efficacy of ACNU vs ACNU + procarbazine as a postoperative chemoradiotherapy was compared in the first clinical trial for astrocytoma grades 3/4 (JCOG 0905). ACNU-based chemoradiotherapy was effective. The median survival durations of glioblastoma patients were 16.8 months and 18.7 months; however, myelosuppression grades 3/4 were observed in more than 40% and 50% of the patients, respectively. Another trial for glioblastoma started this April. The patients are enrolled in either postoperative temozolomide or temozolomide plus Interferon-beta arms and the overall survival is evaluated (JCOG 0901). A clinical trial for metastatic brain tumor is ongoing that compares the results of postoperative overall survival in patients treated with temozolomide monotherapy vs. temozolomide plus interferon beta arms (JCOG 0904). One more trial for primary CNS lymphoma (PCNSL) will be started. CONCLUSION: These results are expected to establish the standard therapy for malignant gliomas and the other malignant brain tumors, such as brain metastasis and PCNSL.
OT-24. HIGH SV2A EXPRESSION IN TUMOR AND PERITUMORAL TISSUE IN GLIOMA PATIENTS WITH EPILEPSY IS ASSOCIATED WITH HIGH EFFICACY OF LEVETIRACETAM

M.de Groot1,2, E. Aarnoudse3, C.J. Veith1, and J.C. Reijneveld1,2; 1Department of Neurology, VU University Medical Center; 2Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands; 3Department of (Neuro)Pathology, Academic Medical Center, Amsterdam, The Netherlands

OBJECTIVES: Epilepsy is a common symptom in patients with glioma. Many antiepileptic drugs are known to interact with anti-neoplastic drugs and corticosteroids. Levetiracetam does not have these interactions and benefits the majority of glioma patients. Unfortunately, not all patients are seizure free on levetiracetam. Synaptic vesicle protein 2A (SV2A) is the binding site for levetiracetam. Possibly, the expression of SV2A in brain tissue correlates with clinical response to levetiracetam. METHODS: Forty glioma patients with epilepsy were recruited. All patients had undergone surgery and were on levetiracetam monotherapy. Treatment with levetiracetam was carried out according to standardized guidelines. Clinical characteristics regarding patient, tumor, and epilepsy history were documented. Follow-up visits were scheduled at six months. Expression of SV2A was determined by means of immunohistochemistry on the surgically removed tumor tissue and adjacent normal brain tissue (if available). RESULTS: The two patient groups lost during follow-up: all three due to tumor progression. After six months, 21 patients (57%) were seizure-free, while six patients (16%) reported a reduction in seizure frequency of >50%. In six patients (15%) levetiracetam was not effective. Three patients (8%) had to switch to a different anti-epileptic drug due to adverse effects. Of the patients with high SV2A expression, 100% showed efficacy of levetiracetam and of the patients with low SV2A expression, 38.5% showed efficacy and 61.5% showed no efficacy (P < 0.01). CONCLUSIONS: Our results indicate that levetiracetam monotherapy is efficacious in reducing seizures in the majority of glioma patients suffering from epilepsy, and high expression of SV2A in tumor and peritumoral tissue appears to predict levetiracetam efficacy.

OT-25. THE EFFICACY OF CEDIRANIB AS MONOTHERAPY AND IN COMBINATION WITH LOMUSTINE COMPARED TO RECURRENT GliOblastoma: A PHASE III RANDOMIZED STUDY

Tracy Batchelor1, Paul Mulholland2, Bert Neyts2, L. B. Nabors2, Mario Campon2, Anne Wick6, Warren Mason2, Tom Mikkelson2, Suracek Phuphanich2, Lynn S. Atish2, John F. DeGroot1, H. R. Gattamaneni12, Lawrence M. Cher13, Mark A. Rosenthal14, Franz Payer15, John Xu16, Qi Liu16, and Martin van den Bent17; 1Massachusetts General Hospital; 2Memorial Sloan-Kettering Cancer Center; 3University of Virginia Health Science Center; 4University of Pittsburgh Medical Center; 5Pfizer

BACKGROUND: Glioblastoma is the most common type, and highest grade, of brain tumor. Glioblastoma is also a highly vascular tumor, with angiogenesis driven by the expression or upregulation of vascular endothelial growth factor (VEGF) and its receptors in both endothelial and glioma cells. Therefore, targeting angiogenic signaling is a rational approach in treating glioblastoma. Cediranib is a highly potent oral VEGF-signaling inhibitor with activity against all three VEGF receptors. REGAL (NCT00777713) is a randomized, parallel-group, multicenter Phase III study comparing cediranib (as monotherapy and in combination with lomustine) with lomustine alone in patients with recurrent glioblastoma. METHODS: Eligible patients had to have had histologic or cytologic confirmation of recurrent glioblastoma, to have received one prior treatment with a temozolomide-containing regimen, and to have not received another VEGF-signaling inhibitor. Patients were randomized (2:2:1 ratio) to receive cediranib monotherapy (30 mg/day orally), cediranib (20 mg/day orally) + lomustine (110 mg/m2 orally, once every 6 weeks), or lomustine (110 mg/m2 orally, once every 6 weeks) + cediranib-matched placebo (20 mg/day orally). The primary endpoint was to determine the relative efficacy of cediranib (either as monotherapy or in combination with lomustine) compared with lomustine alone by independent blinded central radiographic review of progression-free survival (PFS). Secondary endpoints included overall survival (OS), response rate, the proportion of patients alive and progression free at 6 months, assessment of the steroid sparing effects of each treatment, time to deterioration of neurologic function, and quality of life. RESULTS: The Safety Monitoring Board recommended proceeding with the randomized part as planned. These data will take place when 270 deaths have occurred. RESULTS: Between December 2008 and September 2009, 325 patients from 67 centers across 10 countries were randomized to study arms. Full results will be available for presentation at the meeting.

OT-26. CILENGITIDE IN PATIENTS WITH NEWLY DIAGNOSED GliOBlastoma multiFORME AND UNmETHYLATED MGMT GENE PROMOTER: SAFETY RUN-IN RESULTS FROM A RANDOMIZED CONTROLLED PHASE II STUDY (CORE)

Burt Nabors1, Karen Fink2, Tom Mikkelson3, Michael Chan4, John Trusheim3, Sunal Raval3, Christine Hicking5, Jean Henslee-Downey4, Martin Picard1, and David Reardon5; 1University of Alabama at Birmingham; 2Baylor Research Institute, Dallas; 3Henry Ford Health Systems, Detroit; 4Wake Forest University Health Sciences, Winston Salem; 5Monmouth Medical Center, Long Branch, New Jersey & Neuro-Oncology, West Long Branch; 6Merck KGaA, Darmstadt; 7EMD Serono Inc, Rockland; 8Duke University Medical Center, Durham

Cilengitide, a selective alphavbeta3/integrin inhibitor, exhibits concentration-dependent antitumor activity in patients with recurrent glioblastoma multiforme (Read et al. JCO 2008). CORE (Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter) is a randomized, parallel-group, multicenter, open-label, randomized, controlled trial. The initial 6-week safety run-in (SR) used a 3 + 3 design to evaluate stepwise cilengitide intensification over 3 treatment groups: 3 × /week, 4 × /week and 5 × /week. 2000-mg cilengitide was administered intravenously in 30 min by infusion of the effects of intensifying cilengitide on patients with an unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter, which is associated with unresponsiveness to chemoradiotherapy (Pegi et al. NEJM 2005). CORE is a Phase II, multicenter, open-label, randomized, controlled trial. The initial 6-week safety run-in (SR) used a 3 + 3 design to evaluate stepwise cilengitide intensification over 3 treatment groups: 3 × /week, 4 × /week and 5 × /week. 2000-mg cilengitide was administered intravenously in 30 min by infusion.
multiple tyrosine kinase inhibitor that targets the VEGF and PDGF receptors abundant in meningiomas. METHODS: We conducted a Phase II trial for patients with recurrent meningioma (WHO grades I–III, n = 40) or heman-
giopericytoma (n = 3) and atypical meningioma (n = 10). The trial excluded patients with KPS ≤ 70. RESULTS: The enrol
everal cohort consisted of 31 patients (21 female, 10 male) with a median age of 60 (range, 37–84) years and median KPS of 70 (range, 30–100). The drug was administered orally at 50 mg/day for days 1–28 of every 42 day cycle. Magnetic resonance imaging (MRI) scans are performed every cycle for the first two cycles and then every two cycles. The primary endpoint is the 6-month progression-free survival (PFS) rate for elderly patients with newly-diagnosed GBM and poor performance status (KPS < 70). PRELIMINARY RESULTS OF THE ANOCEF “TAG” TRIAL Jaime Gállego Pérez-Larraya1, Jerôme Honnorat2, Olivier Chinot1, Isabelle Cattin1, Laura Taulier8, Luc Taillandier5, Chantal Campello4, Annick Monjour8, Marie L. Tanguy1, and Jean Y. Delatte1; 1CHU Pitié-Salpêtrière; 2CHU Lyon; 3CHU Timone Marseille; 4CHU Bordeaux; 5CHU Nancy; 6CHU Caen; 7CHU Nimes; 8CHU Colmar ABSTRACT: The correct management of glioblastoma (GBM) in elderly patients with a poor Karnofsky performance status (KPS ≤ 70) has not been settled. A trial evaluating the effect of temozolomide alone in this population was undertaken. PATIENTS AND METHODS: Patients aged 70 years or older with newly-diagnosed GBM and a postoperative KPS ≤ 70 were eligible for this multicenter prospective Phase II trial. The treatment consisted of temozolomide (150–200 mg/m²/day) every 4 weeks for a maximum of 12 cycles or until progression. Radiotherapy was not adminis-
tered. RESULTS: Seventy patients (42 female and 28 male) with a median age of 77 (range, 70–87 years) were included between 07/07 and 02/09. The postoperative KPS was 60 in 44 patients (63%) and below 60 in 26 patients (37%). During follow-up, 18 patients (23.7%) achieved a KPS ≤ 70, and 21 patients (30%) improved their score by at least 10 points. An objec-
tive response was observed in 18 patients (26%). The toxicity profile was acceptable, with grade 4 neutropenia and/or thrombocytopenia occurring in 5 patients. The rate of 6-month progression-free survival (PFS) was 29%, with a median PFS of 16 weeks (95% CI, 10–20). The rate of 6-month radiotherapy suggest that this treatment is feasible and safe. The planned dose escalation was based on tolerability to achieve target trough concentrations of 5–5 nmol/L. RESULTS: Median duration of treatment was 21.5 months (range, 4.7–34.1). Twenty-one patients (75.0%) experienced reductions in SEGA volume of ≥ 50% during the first 6 months. Mean reduction in left ventricle volume was 3.22 cm³ and 3.15 cm³, respectively, at month 6. No patient developed a new lesion and none required surgical resec-
tion or other therapy for SEGA. Mean reduction in tumor volume was 3.39 cm³ from baseline to month 6. No change was evident in SEN volume. Among the 16 patients for whom 24-hour vEEG was available at baseline and at month 6, 9 showed reductions, 6 showed no change, and 1 had an increase. Percentage of patients experiencing seizures on a daily basis improved from 27% at baseline to 8% at month 6, based on caregiver observation. CONCLUSIONS: Everolimus offers patients with TS-associated SEGA a viable alternative to sur-
gical resection.

OT-30. A PHASE I TRIAL OF THE PROTEASE INHIBITOR NELFINAVIR AND CONCURRENT RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH WHO GRADE IV GLIOMA Michelle Alonso-Basanta, Robert A. Lustig, and Jay F. Dorsey; University of Pennsylvania BACKGROUND: HIV protease inhibitors (HPI) sensitize glioblastoma cells to radiation in vitro and in vivo via a proposed mechanism of Akt inhibi-
tion. We initiated a Phase I trial to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLT) of the HPI nelfinavir mesylate in combination with concurrent radiation and temozolomide in WHO grade IV glioma. METHODS: The study was designed as an open-label Phase I/II study. Patients with pathologically confirmed grade IV glioma were eligible. A classic 3 + 3 study design was selected. Nelfinavir (625 or 1250 mg orally twice daily) was added to standard concomitant radiation (60 Gy) and temo-
zoamide (75 mg/kg) beginning 5 days after the start of concurrent radiation therapy. The toxicity of nelfinavir in this popu-
lation is concerning and needs further evaluation.

OT-31. FINAL ANALYSIS OF ACT III: A PHASE II TRIAL OF PF-04948568 (CDX-110) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Rose K. Lau1, Lawrence D. Recht2, David A. Reardon3, Nina Paleologos4, Morris Groves5, Myrna R. Rosenfeld6, Sandra Meech7, Tom Davis8, Dmitri Pavlov9†, Margaret A. Marshall7, and John Sampson9; 1Neurological Institute of Columbia University; 2Stanford Cancer Center; 3The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center; 4NorthShore University Health System; 5Evantide Therapeutics; 6Duke University Medical Center; 7Pfizer Global Research and Development; 8Celldex Therapeutics; 9Duke University Medical Center BACKGROUND: EGFRvIII is a constitutively activated mutation of epi-
dermal growth factor receptor (EGFR) expressed in ~25% of glioblastomas (GBMs) but absent in normal tissues, PF-04948568 is a vaccine containing a 13-aa acid sequence unique to EGFRvIII. The study was designed as a multi-center, randomized, open-label Phase IIb/III study in

OT-29. EFFECT OF EVEROLIMUS ON TUBEROUS SCLEROSIS-RELATED LESIONS IN THE BRAIN David N. Franz1, Darcy A. Krueger1, Marguerite M. Care1, Katherine Holland-Bouley1, Karen Agricola1, Cynthia Tudor1, Prajakta Mangeshkar1, Anna W. Byars1, and Tarek Sahmoud2; 1Cincinnati Children’s Hospital Medical Center; 2Novartis Pharmaceuticals Corporation BACKGROUND: Tuberous sclerosis (Ts) is a potentially devastating dis-
order caused by mutations in TSC1 or TSC2 that result in constitutive mTOR activation. Ts is characterized by hamartoma formation in multiple systems and is associated with epilepsy, rhabdomyosarcoma, and renal tumors. Historically, treatment options included surgical resection of affected organs, radiation, and immunosuppression. However, these approaches are limited by morbidity and mortality. More recently, mTOR inhibitors such as everolimus have demonstrated antiproliferative effects in cell culture and in vitro in cell cultures to radiation. CONCLUSIONS: Early results of the Phase I study indicate that this treatment is feasible and safe. The planned dose escalation was based on tolerability to achieve target trough concentrations of 5–5 nmol/L. RESULTS: Median duration of treatment was 21.5 months (range, 4.7–34.1). Twenty-one patients (75.0%) experienced reductions in SEGA volume of ≥ 50% during the first 6 months. Mean reduction in left ventricle volume was 3.22 cm³ and 3.15 cm³, respectively, at month 6. No patient developed a new lesion and none required surgical resec-
tion or other therapy for SEGA. Mean reduction in tumor volume was 3.39 cm³ from baseline to month 6. No change was evident in SEN volume. Among the 16 patients for whom 24-hour vEEG was available at baseline and at month 6, 9 showed reductions, 6 showed no change, and 1 had an increase. Percentage of patients experiencing seizures on a daily basis improved from 27% at baseline to 8% at month 6, based on caregiver observation. CONCLUSIONS: Everolimus offers patients with TS-associated SEGA a viable alternative to sur-
gical resection.
the United States and was amended to a single-arm design after 14/16 patients (pts) randomized to the standard-of-care arm withdrew after notification of treatment assignment. The primary objective was to reject the hypothesis of no effect of 4 concurrent ultrafractionation regimen and temozolomide for inoperable glioblastoma patients. METHODS: A prospective, multicenter, Phase II study opened for accrual in February 2008. Patients over 18 years of age who are able to give informed consent and have histologically proved, newly diagnosed, inoperable, and supratentorial glioblastoma are eligible. accrual is expected to be completed by at least 4 hours after a dose of 75 mg/m², 7 days per week during the ultrafractionated radiotherapy. After radiotherapy is completed, patients will continue to receive concomitant temozolomide every 28 days, according to the standard 5-day regimen. Tolerance and toxicity are the primary endpoints; survival and progression-free survival (PFS) are secondary endpoints. RESULTS: To date, 31 patients have been enrolled in this study, 22 of whom are evaluable. The median age was 62, and a median Karnofsky Performance Status (KPS) of 80. Concomitant ultrafractionated radiotherapy–temozolomide has been well tolerated; no acute grade 3 and/or 4 central nervous system (CNS) toxicity has been observed. Stabilization of progression-free and overall survival was seen in all patients. The median survival from initial diagnosis was 9.5 months and 2 patients remain alive. The median KPS was 51 months. The overall survival (OS) rates at 18 and 24 months were 19% and 15%, respectively. CONCLUSIONS: Ultrafractionated radiation is safe and may prolong the survival of patients with glioblastoma. Further investigation is warranted and a trial associating ultrafractionation and temozolomide is ongoing.

OT-34. SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND IRINOTECAN (CPT-11) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GliOBLASTOMA MULTIFORME (GBM) PATIENTS

Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, IL, John P. Kirkpatrick, Henry S. Friedman, and James J. Vredenburgh; Duke University Medical Center

BACKGROUND: Newly diagnosed glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ) and radiation therapy (RT), followed by 6 monthly cycles of TMZ have median progression-free survival (PFS) and median overall survival (OS) rates of 6.9 and 15.9 months, respectively. Bevacizumab (BV) has demonstrated a significant therapeutic benefit for recurrent GBM. This study aimed to evaluate the benefit of incorporating BV with RT and TMZ, and CPT-11 and BV to TMZ post-RT therapy for newly diagnosed GBM patients. METHODS: Patients received standard RT and BV at 10 mg/kg/wk plus TMZ at 75 mg/m² for 4 weeks, followed by a 4 week break, then chemotherapy is resumed, with up to 6 cycles of adjuvant temozolomide every 28 days postoperatively. Afterward, patients received 6 to 12 cycles of TMZ, BV, and CPT-11 (28-day cycle). TMZ was given at a dose of 200 mg/m² on days 1–5, BV and CPT-11 were given on days 1 and 15; BV was given at a dose of 10 mg/kg and CPT-11 at a dose of 125 mg/m² for patients not on an enzyme-inducing antiepileptic drug (EIAED) and at a dose of 340 mg/m² for patients on an EIAED. RESULTS: For the first 75 patients enrolled, at a median follow-up of 23 months, the median PFS is 14.5 months and the median OS is 21.2 months. One-year and 2-year OS are 79% and 45%, respectively, PFS rates at 1 and 2 years are 63% and 14%, respectively. For recursive partitioning analysis (RPA) class 3, 1-year OS was 100% and 2-year OS was 68%. For RPA class 4, OS dropped from 90% at 1 year to 39% at 2 years. Toxicities for all 125 enrolled patients included 1 CNS hemorrhage, 9 severe thromboembolic events, 1 bowel perforation, 17 grade 4 hematologic toxicities, 1 secondary malignancy (AML), and 2 pneumonias of Pneumocystis jiroveci. CONCLUSION: Adding BV to TMZ and RT followed by BV, TMZ, and CPT-11 is tolerable and efficacious. Updated survival and toxicity results for the whole group of 125 patients enrolled will be presented.

OT-35. RADIOTherAPY (RT) AND TEMOZOLomIDE (TMZ) FOR ANAPLASTIC AstroCYTOMA (AA)

Lakshmi Nayak, Katherine S. Panagia, Lisa M. Deangelis, Lauren A. Abrey, and Andrew B. Lassman; Memorial Sloan-Kettering Cancer Center

BACKGROUND: Anaplastic astrocytomas (AA) are aggressive tumors with a median survival of 24–36 months. Combined radiotherapy (RT) and temozolomide (TMZ) is well established as the standard of care for newly diagnosed glioblastoma, but its applicability to anaplastic astrocytoma (AA) is controversial. We conducted a randomized Phase II study in malignant glioma of RT + TMZ followed by either metronomic or dose-dense adjuvant TMZ, followed by cis-retinoic acid (c-RA). We previously reported results for the GBM cohort and now describe the outcomes for patients with anaplastic gliomas. PATIENTS AND METHODS: Following maximal surgical resection with concurrent adjuvant newly diagnosed AA or anaplastic oligo-astrocytoma (AOA), with an age ≥18, and KPS ≥60 were treated with concurrent RT (60 Gy over 6 weeks) + TMZ (75 mg/m²), and then 6 adjuvant 28-day cycles of either dose-dense (15 mg/m², days 1–7; 17–21) or metronomic (50 mg/m², days 1–28) TMZ. Follow-up was complete in all patients. CONCLUSION: Median OS of patients receiving c-RA

IV77

Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/12/suppl_4/iv69/1522764 by guest on 08 March 2019
(100 mg/m^2, days 1–21/28) was administered until disease progression. MGMT promoter methylation was assessed when possible. RESULTS: There were 30 patients enrolled from 8/2003–12/2009, 21 of whom were men, with a median age of 48.5 (range, 20 to 74 years). Median KPS was 90 (60–100). Eleven patients underwent gross total resection, 7 underwent subtotal resection, and 12 underwent biopsy. Twenty-seven had AA and 3 had AOA. MGMT was methylated in 6, unmethylated in 12, and unknown in 3. Five had MRD more than 10 years, 2 had MRD less than 10 years, and 1 had MRD without data. Median KPS was 50 (30–60). Four patients underwent radiation therapy, 1 underwent chemotherapy, and 1 underwent both. CONCLUSION: Median survival was 49 months, with a median follow-up duration of 29.3 months on 20 surviving patients. Early analysis did not show any significant difference in survival between AA/ AOA or between treatment arms. CONCLUSION: Median survival following che- moradiotherapy for anaplastic gliomas (AA or AOA) was 40.9 months. Patient follow-up and MGMT analysis continue. More mature results and multivariate analyses will be presented at the meeting.

PATHOLOGY

PA-01. POSTERIOR SPINAL COLUMN METASTASIS OF CLEAR CELL CARCINOMA OF THE LUNG
Erol Tasdemiroglu, Miklari Kaya, and Can H. Yildirim; Kaftas University Medical Faculty

Clear cell carcinoma of the lung is extremely rare. A 48-year-old man presented with severe back pain and a subcutaneous mass located dorsally at the midline between the L2 and T11 levels. The patient’s neurological exam was normal. Magnetic resonance imaging of the thoracic spine showed a posteriorly located lesion between the L2 and T11 levels that invaded both pedicles and the laminae and spinous processes of these vertebrae. The patient underwent surgery, and gross total tumor resection was accomplished. His postoperative period was uneventful. The histopathological diagnosis was metastasis of clear cell carcinoma of the lung. Histopathology was confirmed with immunohistochemistry and computed tomography of the thorax.

PA-02. DETECTION OF CYTOMEGALOVIRUS PP65 AND IE-1 PROTEINS FROM Glioblastoma Multiforme
Kenneth G. Lucas, Lei Bao, Richard Bruggeman, and Charles Specht; Penn State Hershey Medical Center

Cytomegalovirus (CMV) is a latent herpesvirus infecting approximately half of the world’s population. Recent series have shown variable expression patterns of CMV in tumor specimens from patients with malignant glioma. We report the largest single-institution series to date on the expression of CMV pp65 and IE-1, 2 of the most immunogenic CMV proteins, on glioblas- toma multiforme (GBM). In our series, 25 of 49 tumors were positive for pp65, and 8 of the 49 tumors were positive for IE-1. Of the 8 tumors that were positive for both, 7 were also positive for pp65. Not all cells within a given tumor that tested positive for pp65 or IE-1 had staining for these anti- gens, possibly reflecting variability in the infection of GBM cells. Although cells that are permissively infected by CMV, such as skin fibroblasts, have profound nuclear staining, GBM cells that are infected by CMV may show cytoplasmic staining as well. In our series, generally had pp65 and IE-1 cytoplasmic staining. CMV pp65 and IE-1 nuclear staining was seen in approximately half of the GBM. These find- ings could be due to alterations in CMV life cycle and virus production within infected tumor cells, as reported by other groups. We infected GBM cell lines exogenously with laboratory strains of CMV and demonstrated that most tumor cells only had cytoplasmic staining, with some also having pernuclear localization of IE-1. These findings confirm that CMV proteins are present in a subset of GBM and suggest that CMV pp65 and IE-1 could be targeted in an immunotherapy strategy for GBM patients.

Further studies are needed to better define the behavior of CMV-infected tumor cells and determine whether they can be recognized by CMV-specific T cells.

PA-03. EMBRYONAL TUMOR WITH ABUNDANT NEUROPILOT AND TRUE ROSETTES: OLDEST REPORTED CHILD WITH A RARE CENTRAL NERVOUS SYSTEM TUMOR
Jeffrey G. Murray, David J. Donahue, and Carlos A. Galliani; Cook Children’s Medical Center

INTRODUCTION: Pediatric central nervous system (CNS) embryonal neoplasms represent a unique group of primitive neuroectodermal tumors (PNETs) whose unifying features include poorly differentiated cells, the capacity to differentiate along multiple cell lineages, the propensity to disseminate throughout the neuraxis, and aggressive clinical behavior. PNETs are typically classified as medulloblastomas (cerebellar PNETs), CNS PNETs (other-location PNETs), or atypical teratoid/rhabdoid tumors. A novel embryonal tumor, the embryonal tumor with abundant neuropil and true rosettes (ETANTR), a rare PNET that has been reported in 29 children worldwide, has recently been characterized. ETANTR appears to affect primarily young children, has a female predominance, occurs primarily in the cere- bral cortex, and carries a dismal prognosis. METHODS: A 5-year, 2- month-old girl presented with a several week history of headaches, ataxia, and photophobia. Examination revealed papilledema. Magnetic resonance imaging revealed a 5.1 cm × 7.4 cm × 6 cm poorly enhancing mass see- mingly arising from the right lateral ventricle. Gross total resection was achieved, and there was no evidence of neuraxis metastases. RESULTS: Histopathology revealed a cellular lesion with features suggestive of ependym- oma. However, abundant neuropil, ependymoblastoma true rosettes, nuclear pleomorphism, GFAP reactivity, vimentin reactivity, a high MIB-1, and retention of INI1 nuclear expression resulted in a diagnosis of ETANTR. CONCLUSIONS: ETANTR is now recognized as a distinct type of CNS embryonal tumor/PNET despite having only been reported in 29 children to date. As with all forms of CNS PNETs affecting children less than 3 years old, ETANTR appears to connote a poor prognosis. Our case represents the oldest child with ETANTR yet reported, suggesting that the age spectrum may expand as more is understood about this disorder. Our patient is receiving aggressive therapy including cranioplastic radiotherapy and chemotherapy. Her older age may portend a better prognosis, as has been observed in patients with other types of PNET.

PA-04. T-CELL RECEPTOR-GAMMA SUBUNIT GENE REARRANGEMENT ANALYSIS AS AN ADJUNCTIVE DIAGNOSTIC STRATEGY IN PRIMARY MENINGEAL T-CELL NON-HODGKIN LYMPHOMA
Nicholas A. Blondin, 1 Pei Hu, 2 Alexander Vortmeyer, 2 Joshua Hashani, 1 and Joachim Baehring 1; Yale-New Haven Hospital; 2Yale University School of Medicine

Primary CNS lymphoma accounts for 3% of all primary brain neoplasms. The vast majority of these tumors are derived from the B-cell lineage. While meningeal involvement occurs in 5–20% of patients, primary meningeal manifestations are rare and pose a diagnostic challenge, especially in T-cell lymphomas. Radiographic features are nonspecific, and the sensitivity of morphology-based analysis and flow cytometry is insufficient. We used a multiplex polymerase chain reaction/capillary electrophoresis–based method to detect clonal rearrangements of the gene encoding the gamma subunit of the T-cell receptor in 2 patients with primary meningeal T-cell lymphoma. The first patient was a 22-year-old African-American man who initially presented with generalized seizures and was found to have a rapidly growing mass in the right temporal lobe. A brain biopsy revealed a monochonal population of T-lymphocytes. The patient’s disease went into remission following chemotherapy and radiation therapy; however, the patient subsequently developed a biopsy-confirmed metastatic T-cell lymphoma lesion in the abdominal subcutaneous tissue approximately 15 months later. He later achieved a second remission with chemotherapy. The second patient was a 30-year-old Caucasian man who initially presented with headaches, a left abducens nerve palsy, and progressive left-sided radi- calulopathy. A lumbar puncture was performed, and while cerebrospinal fluid cytopathology and flow cytometry suggested a diagnosis of primary menin- geal T-cell lymphoma, T-cell receptor-gamma gene rearrangement analysis confirmed the diagnosis without need for a brain biopsy. The patient achieved remission following treatment with chemotherapy. We will present the radiographic findings, cytopathology, flow cytometry, and mole- cular pathology methodology and data for these 2 cases. Clonality analy- sis based on rearrangement analysis of the gene encoding the gamma subunit of the T-cell receptor may be a useful adjunct to conventional diagnostic methods in patients with T-cell lymphoma of the nervous system.

PA-05. MOLECULAR MARKERS OF HYPOXIA, VASCULARITY, AND IMAGING TO PREDICT OUTCOMES OF PATIENTS WITH INTRACRANIAL MENINGIOMAS
Randy I. Jensen and Janet Lee; Huntsman Cancer Institute, University of Utah

BACKGROUND: Intracranial meningiomas, even those of a WHO grade I, have a wide variation in natural history. No fail-proof method for predict- ing recurrence and patient outcome currently exists. This study explored multiple factors including tumor histology, markers, preoperative imaging,

iv78

NEURO-ONCOLOGY  •  NOVEMBER 2010